Investors Shareholders

About
Teams
Sustainability
Investments
Media

Important notice

Current portfolio

Eloxx Pharma

Developing Therapeutics to treat genetic diseases

Sector
Healthcare
Country
United States
Fund
LSP 5
Entry
2017
Web
eloxxpharma.com

Sector
Healthcare
Country
United States
Fund
LSP 5
Entry
2017
Web
eloxxpharma.com

Eloxx Pharma

Latest news

18 November 2024
EQT Life Sciences leads €54 Million Series A Financing of ATB Therapeutics
18 November 2024
EQT Exeter to Acquire Strategic Supply Chain Assemblage Comprising Nearly Five Million Square Feet of Institutional Quality Industrial Assets
17 November 2024
EQT sets hard cap for EQT Private Capital Asia’s BPEA IX at USD 14.5 billion
05 November 2024
EQT X, through Oak BidCo S.à r.l., has secured an ownership of 72.5% of the votes in OEM International Aktiebolag (publ) and announces a Cash Offer to all shareholders
31 October 2024
EQT Exeter to acquire 94,000 square-meters across four warehouses in Germany

0

Subscribe for the latest updates

Subscribe to EQT's press releases, regulatory press releases and updates.

Type of news

Regulatory News

EQT News

Preferred languageEnglishSwedish

Email address

Offices

Europe
North America
- New York
- San Francisco
APAC

About

EQT Playbook
Fund investors
Purpose and Culture
EQT Foundation
- EQT Foundation
Careers
- Life at EQT
- EQT Academy
Motherbrain

Teams

Roles

Sustainability

Future-proofing

Business Segments

Private Capital
Real Assets

Investments

Portfolio

Shareholders

About EQT AB Group
IPO on Nasdaq Stockholm
Reports and Presentations
Corporate Governance
About the Share

Media

Newsroom
- News
- Reports and presentations

Contact

Media
- Press Contact
Follow

Legal

Sustainable Finance Disclosure
Complaints Handling Procedure
Glossary and Definitions
Policies
EQT Cookie Notice
Terms and Conditions

About

Teams

Sustainability

Investments

Shareholders

Media

Contact

Legal

A purpose-driven global investment organization

© EQT AB 2022. EQT AB (PUBL). REGISTRATED OFFICE IN STOCKHOLM, SWEDEN. REGISTRATION NUMBER: 556849-4180